OVERVIEW
Happy Saturday
Welcome to the Stocks Top 25 Newsletter this week!
The Stocks Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!
Here are the Stocks Top 25 Lists for this week:
S&P 500
Top 25 S&P 500
The S&P 500 Top 25 list (+2.65%)outperformed the S&P 500 index (+1.92%).
There were 2 major changes to the list this week.
NASDAQ 100
The Large-Cap Nasdaq 100
The Nasdaq 100 Top 25 list (+3.14% ) outperformed the Nasdaq 100 index (+2.18%).
There were 2 major changes to the list this week.
RUSSELL 2000
The Growth-Centric Russell 2000
The Russell 2000 Top 25 list (0.91%) underperformed the Russell 2000 index (2.50%).
There were 4 major changes to the list this week.
Top Dawg Of The Week
The Top 25 list's Top Dawg was $INBX ( 0.0% ), which rallied nearly 54% to an all time high.
- Inhibrx Biosciences announced Friday that its drug Ozekibart yielded positive results in a registrational trial for a rare type of bone cancer.
- In the study, Ozekibart achieved a 52% reduction in the risk of disease progression or death compared to placebo, more than doubling median progression-free survival to 5.52 months.
- According to Inhibrx, Ozekibart is the first investigational therapy to demonstrate a significant PFS benefit in a randomized trial for chondrosarcoma.
INBX is up 272% YTD.
